213 related articles for article (PubMed ID: 30392789)
1. NEO212, a conjugate of temozolomide and perillyl alcohol, blocks the endothelial-to-mesenchymal transition in tumor-associated brain endothelial cells in glioblastoma.
Marín-Ramos NI; Jhaveri N; Thein TZ; Fayngor RA; Chen TC; Hofman FM
Cancer Lett; 2019 Feb; 442():170-180. PubMed ID: 30392789
[TBL] [Abstract][Full Text] [Related]
2. NEO212 Inhibits Migration and Invasion of Glioma Stem Cells.
Marín-Ramos NI; Thein TZ; Cho HY; Swenson SD; Wang W; Schönthal AH; Chen TC; Hofman FM
Mol Cancer Ther; 2018 Mar; 17(3):625-637. PubMed ID: 29440289
[TBL] [Abstract][Full Text] [Related]
3. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
4. NEO212, temozolomide conjugated to perillyl alcohol, is a novel drug for effective treatment of a broad range of temozolomide-resistant gliomas.
Cho HY; Wang W; Jhaveri N; Lee DJ; Sharma N; Dubeau L; Schönthal AH; Hofman FM; Chen TC
Mol Cancer Ther; 2014 Aug; 13(8):2004-17. PubMed ID: 24994771
[TBL] [Abstract][Full Text] [Related]
5. Metformin treatment reduces temozolomide resistance of glioblastoma cells.
Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y
Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206
[TBL] [Abstract][Full Text] [Related]
6. SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells.
Tang H; Zhao J; Zhang L; Zhao J; Zhuang Y; Liang P
Cell Mol Neurobiol; 2016 Oct; 36(7):1067-76. PubMed ID: 26643178
[TBL] [Abstract][Full Text] [Related]
7. Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition.
Krishnan S; Szabo E; Burghardt I; Frei K; Tabatabai G; Weller M
Oncotarget; 2015 Sep; 6(26):22480-95. PubMed ID: 26090865
[TBL] [Abstract][Full Text] [Related]
8. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
9. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Gilbert CA; Daou MC; Moser RP; Ross AH
Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377
[TBL] [Abstract][Full Text] [Related]
10. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
[TBL] [Abstract][Full Text] [Related]
11. Overview of Transforming Growth Factor β Superfamily Involvement in Glioblastoma Initiation and Progression.
Nana AW; Yang PM; Lin HY
Asian Pac J Cancer Prev; 2015; 16(16):6813-23. PubMed ID: 26514451
[TBL] [Abstract][Full Text] [Related]
12. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway.
Zhou X; Chen X; Cai JJ; Chen LZ; Gong YS; Wang LX; Gao Z; Zhang HQ; Huang WJ; Zhou H
Drug Des Devel Ther; 2015; 9():4599-611. PubMed ID: 26316699
[TBL] [Abstract][Full Text] [Related]
13. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
14. Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
Cheng YC; Tsai WC; Sung YC; Chang HH; Chen Y
Cell Physiol Biochem; 2018; 45(2):819-831. PubMed ID: 29414809
[TBL] [Abstract][Full Text] [Related]
15. Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition.
Matias D; Balça-Silva J; Dubois LG; Pontes B; Ferrer VP; Rosário L; do Carmo A; Echevarria-Lima J; Sarmento-Ribeiro AB; Lopes MC; Moura-Neto V
Cell Oncol (Dordr); 2017 Jun; 40(3):247-261. PubMed ID: 28401486
[TBL] [Abstract][Full Text] [Related]
16. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
17. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
18. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.
Oliveira-Ferrer L; Wellbrock J; Bartsch U; Penas EM; Hauschild J; Klokow M; Bokemeyer C; Fiedler W; Schuch G
Mol Cancer; 2013 Nov; 12(1):144. PubMed ID: 24257371
[TBL] [Abstract][Full Text] [Related]
20. A New Investigational Perspective for Purines Against Glioblastoma Invasiveness.
Giuliani P; Zuccarini M; Carluccio M; Ziberi S; Di Iorio P; Caciagli F; Ciccarelli R
Curr Drug Targets; 2018; 19(16):1871-1881. PubMed ID: 29484991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
